This Morning's Technical Outlook on Drug Makers Stocks -- Bristol-Myers Squibb, Eli Lilly, AbbVie, and Johnson & Johnson

Monday, December 4, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Dec. 4, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information,

WallStEquities.com has issued free tailored Stock Review on BMY, LLY, ABBV, and JNJ which is a click away at www.wallstequities.com/registration. Today, WallStEquities.com redirects attention to the Pharmaceutical industry, which discovers, develops,
produces, and markets drugs or pharmaceutical drugs for use as medications. Four major players in the Drug Manufacturers space have been lined up for assessment, and they are Bristol-Myers Squibb Co. (NYSE: BMY), Eli Lilly and Co. (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). With Wall St. Equities' free research reports getting an edge over stock markets, sign up now at: www.wallstequities.com/registration

Bristol-Myers SquibbNew York headquartered Bristol-Myers Squibb Co.'s stock rose 0.08%, finishing last Friday's trading session at $63.24. A total volume of 4.15 million shares was traded. The Company's shares have gained 1.74% in the last month, 5.58% over the previous three months, and 8.21% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 0.63% and 9.49%, respectively. Additionally, shares of Bristol-Myers Squibb have a Relative Strength Index (RSI) of 57.86.  

On November 30th, 2017, Bristol-Myers Squibb announced that it will take part in the Citi 2017 Global Healthcare Conference on December 06th, 2017, in New York. Murdo Gordon, Chief Commercial Officer, will answer questions about the Company at 2:55 p.m. ET. A live webcast of the session will be available on the Company's investor website. Our free and thorough report on BMY awaits you at: www.wallstequities.com/registration/?symbol=BMY

Eli LillyShares in Indiana headquartered Eli Lilly and Co. ended at $85.32, up 0.80% from the last trading session. The stock recorded a trading volume of 2.74 million shares. The Company's shares have advanced 2.93% in the past month, 6.54% over the previous three months, and 16.00% since the start of this year. The stock is trading 0.76% and 3.18% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Eli Lilly have an RSI of 58.51.  

On November 20th, 2017, Eli Lilly announced that it will release its financial guidance for 2018 on December 13th, 2017. The Company will also conduct a conference call with the investment community and media at 10:00 a.m. ET that day to further detail its guidance. A live webcast of the call will be available on the Company's investor website. LLY's complimentary research coverage is a few simple steps away at:

www.wallstequities.com/registration/?symbol=LLY

AbbVieOn Friday, shares in Illinois-based AbbVie Inc. recorded a trading volume of 4.82 million shares. The stock declined 0.62%, closing the day at $96.32. The Company's shares have gained 4.20% in the last one month, 27.71% over the previous three months, and 53.82% on an YTD basis. The stock is trading 4.44% above its 50-day moving average and 28.21% above its 200-day moving average. Additionally, shares of AbbVie have an RSI of 62.04.  

On November 21st, 2017, AbbVie announced that the American Society of Hematology (ASH) has accepted data from the Phase 3 MURANO study evaluating venetoclax tablets, in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia, as an oral, late-breaking presentation during the upcoming 59th ASH Annual Meeting & Exposition, which will be held from December 09th, 2017 to December 12th, 2017 in Atlanta, Georgia. The abstract is one of six, late-breaking abstracts accepted for presentation at the meeting. Register for your free research report on ABBV at: www.wallstequities.com/registration/?symbol=ABBV

Johnson & Johnson

At the close of trading on Friday, shares in New Jersey-based Johnson & Johnson recorded a trading volume of 5.98 million shares, which was higher than their three months average volume of 5.33 million shares. The stock finished the session 0.47% higher at $139.98. The Company's shares have gained 6.83% in the previous three months and 21.50% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.85% and 6.84%, respectively. Furthermore, shares of the Company have an RSI of 58.68.  

On November 30th, 2017, Johnson & Johnson announced that it will participate in the BMO Capital Markets Healthcare Conference on December 14th, 2017, at the Westin Grand Central in New York, NY. Sandi Peterson, Executive Vice President - Group Worldwide Chairman, will represent the Company in a session scheduled at 8:30 a.m. ET. This webcast will be available on the Company's investor website. Wall St. Equities' downloadable research report on JNJ is available at: www.wallstequities.com/registration/?symbol=JNJ

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-drug-makers-stocks----bristol-myers-squibb-eli-lilly-abbvie-and-johnson--johnson-300565771.html

SOURCE Wall St. Equities



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store